Search Within

Saad Zafar Usmani

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (9)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (35)
  2. Center for Hematologic Malignancies (34)
  3. Department of Medicine (34)
  4. Hematologic Malignancies, Division of (34)
  5. Myeloma (34)
  6. Hematologic Malignancies Research (33)

More Groups

People
  1. Alexander Lesokhin (32)
  2. Neha Korde (27)
  3. David Chung (25)
  4. Heather Landau (25)
  5. Kylee Maclachlan (25)
  6. Sham Mailankody (25)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (15)
  4. 2022 (10)
Publications
  1. Blood (15)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Blood Advances (2)
  4. Journal of Clinical Oncology (2)
  5. New England Journal of Medicine (2)
  6. Cancer Cell (1)

More Publications

Publishers
  1. American Society of Hematology (17)
  2. Elsevier Inc. (11)
  3. American Society of Clinical Oncology (2)
  4. Massachusetts Medical Society (2)
  5. Cell Press (1)
  6. Nature Research (1)

More Publishers

Results (35)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
    Journal Article

    Cirrincione, A. M.; Poos, A. M.; Ziccheddu, B.; Kaddoura, M.; Bärtsch, M. A.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; John, L.; Reichert, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save